Japan price cuts loom less
This article was originally published in The Gray Sheet
Executive SummaryAdvaMed is "cautiously optimistic" that upcoming biannual cuts in reimbursement for medical devices in Japan will be in aggregate less severe than in the past, the trade group's CEO Steve Ubl said. Japan's MHLW has already released its proposal to manufacturers, who have the opportunity to raise objections. The final reimbursement levels, which take effect April 1, are expected to be released shortly. The device industry continues to lobby against Japan's use of foreign average pricing and other measures to reduce device payments (1"The Gray Sheet" Oct. 8, 2007, p. 3)
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.